TamilJohnson & Johnson claims its single-shot COVID-19 vaccine neutralises Delta variant
2 July 2021, 2:29 pm
Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration - RC23PL9K8PD3
Johnson & Johnson on Thursday (July 1, 2021) announced findings from a small laboratory study, which revealed that the single-shot vaccine neutralizes the fast-spreading delta variant of COVID-19 and provides durable protection against infection. According to the company report, the vaccine jab generated strong, persistent activity against the Delta variant and other highly prevalent SARS-CoV-2 viral variants.
The data from the laboratory study revealed that the durability of the immune response lasted for at least eight months. The report also stated that the single-dose vaccine, elicited neutralising antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant in South Africa.
Additionally, it said that Johnson & Johnson’s vaccine demonstrated protection against hospitalisation and death, and provided 85 percent effectiveness against critical infections.
0
0